Compare · CEMI vs ORKA
CEMI vs ORKA
Side-by-side comparison of Chembio Diagnostics Inc. (CEMI) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CEMI and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.47B, about 258.8x CEMI ($25.0M).
- ORKA has hit the wire 14 times in the past 4 weeks while CEMI has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 1 for CEMI).
- Company
- Chembio Diagnostics Inc.
- Oruka Therapeutics Inc.
- Price
- $0.46+2.63%
- $95.23-2.56%
- Market cap
- $25.0M
- $6.47B
- 1M return
- -
- -13.10%
- 1Y return
- -
- +474.05%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 14
- Recent ratings
- 1
- 11
Chembio Diagnostics Inc.
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, Hepatitis C, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, Rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
Latest CEMI
- SEC Form 15-12G filed by Chembio Diagnostics Inc.
- SEC Form SC 13D/A filed by Chembio Diagnostics Inc. (Amendment)
- SEC Form EFFECT filed by Chembio Diagnostics Inc.
- SEC Form EFFECT filed by Chembio Diagnostics Inc.
- SEC Form EFFECT filed by Chembio Diagnostics Inc.
- SEC Form EFFECT filed by Chembio Diagnostics Inc.
- SEC Form EFFECT filed by Chembio Diagnostics Inc.
- SEC Form 4 filed by Angelico Paul
- SEC Form 4 filed by Acheson David
- SEC Form 4 filed by Eberly Richard
Latest ORKA
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $734,145 worth of shares (7,947 units at $92.38) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 31,771 units (SEC Form 4) (for tax liability)
- Senior Vice President, Finance Agarwal Arjun sold $926,010 worth of shares (10,019 units at $92.43) as part of a pre-agreed trading plan and exercised 9,459 shares at a strike of $15.88, decreasing direct ownership by 4% to 14,752 units (SEC Form 4) (for tax liability)
- Chief Executive Officer Klein Lawrence Otto sold $234,681 worth of shares (2,452 units at $95.71), decreasing direct ownership by 0.26% to 923,128 units (SEC Form 4) to cover withholding tax
- General Counsel Quinlan Paul T sold $99,443 worth of shares (1,039 units at $95.71), decreasing direct ownership by 3% to 29,995 units (SEC Form 4) to cover withholding tax
- Chief Operating Officer Sandler Laura Lee sold $86,713 worth of shares (906 units at $95.71), decreasing direct ownership by 0.38% to 235,478 units (SEC Form 4) (withholding tax)
- Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $459,101 worth of shares (5,000 units at $91.82) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Klein Lawrence Otto exercised 75,000 shares at a strike of $7.80 and sold $6,887,484 worth of shares (75,000 units at $91.83) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- SEC Form EFFECT filed by Oruka Therapeutics Inc.